Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Nxera Pharma Announces Exclusive Supply Agreement with Handok for Pivlaz™
Details : Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Brand Name : Pivlaz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 14, 2024
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CHC2014
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : AUM Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AUM-601 (CHC2014), a selective second-generation “Pan-TRK” Inhibitor was safe and well-tolerated at dose levels of 50 to 300 mg QD, as recommend Phase 2 dose (RP2D) based on PK profile and safety results.
Brand Name : AUM601
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : CHC2014
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : AUM Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CHC2014
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AUM Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
AUM Biosciences enters in a Strategic Collaboration with Handok and CMG Pharm to develop CHC2014
Details : CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registrational program. CHC2014 has shown superior in-vivo anti-tumor activity compared to available treatment options.
Brand Name : CHC2014
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 11, 2021
Lead Product(s) : CHC2014
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AUM Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?